Search

Your search keyword '"Callander, Natalie"' showing total 471 results
Start Over Author "Callander, Natalie" Language english
471 results on '"Callander, Natalie"'

1. Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma

Author

Mikhael, Joseph, Baljevic, Muhamed, Landgren, C. Ola, Valdes, Cesar Rodriquez, Usmani, Saad Z., Callander, Natalie, and Richter, Joshua

Subjects
T cells, Multiple myeloma, Health
Abstract

The assessment of updated clinical trial data, optimal dosing strategies, and integration of bispecific antibodies into current relapsed/refractory multiple myeloma treatment paradigms were the focus of conversation during a Frontline [...]

Published
2024

2. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Author

Callander, Natalie S., Silbermann, Rebecca, Kaufman, Jonathan L., Godby, Kelly N., Laubach, Jacob, Schmidt, Timothy M., Sborov, Douglas W., Medvedova, Eva, Reeves, Brandi, Dhakal, Binod, Rodriguez, Cesar, Chhabra, Saurabh, Chari, Ajai, Bal, Susan, Anderson, Jr, Larry D., Dholaria, Bhagirathbhai R., Nathwani, Nitya, Hari, Parameswaran, Shah, Nina, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Giri, Smith, Costa, Luciano J., Usmani, Saad Z., Richardson, Paul G., and Voorhees, Peter M.

Published
2024
Full Text
View/download PDF

4. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Author

Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas S, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa McKiver, Mihaela, Cook, Mark, and Rodríguez-Otero, Paula

Published
2024
Full Text
View/download PDF

6. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Author

Ailawadhi, Sikander, Arnulf, Bertrand, Patel, Krina, Cavo, Michele, Nooka, Ajay K., Manier, Salomon, Callander, Natalie, Costa, Luciano J., Vij, Ravi, Bahlis, Nizar J., Moreau, Philippe, Solomon, Scott, Abrahamsen, Ingerid Weum, Baz, Rachid, Broijl, Annemiek, Chen, Christine, Jagannath, Sundar, Raje, Noopur, Scheid, Christof, Delforge, Michel, Benjamin, Reuben, Pabst, Thomas, Iida, Shinsuke, Berdeja, Jesús, Giralt, Sergio, Truppel-Hartmann, Anna, Chen, Yanping, Zhong, Xiaobo, Wu, Fan, Piasecki, Julia, Eliason, Laurie, Dhanda, Devender, Felten, Jasper, Caia, Andrea, Cook, Mark, Popa McKiver, Mihaela, and Rodríguez-Otero, Paula

Published
2024
Full Text
View/download PDF

9. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Author

Costa, Luciano J, Chhabra, Saurabh, Medvedova, Eva, Dholaria, Bhagirathbhai R, Schmidt, Timothy M, Godby, Kelly N, Silbermann, Rebecca, Dhakal, Binod, Bal, Susan, Giri, Smith, D'Souza, Anita, Hall, Aric C, Hardwick, Pamela, Omel, James, Cornell, Robert F, Hari, Parameswaran, and Callander, Natalie S

Published
2023
Full Text
View/download PDF

10. The Management of Relapsed and Refractory Multiple Myeloma

Author

Gahvari, Zhubin J. and Callander, Natalie S.

Subjects
Diseases -- Relapse, Carfilzomib, Health
Abstract

The treatment of patients with relapsed and refractory multiple myeloma has become increasingly complex due to the rising number of available therapies. Patients are also increasingly exposed to, and refractory to, multiple classes of therapy at the time of progression. Patients who are at an early point in their myeloma disease course are likely to have several effective options, but choices and prognosis are limited for relapsing patients who are more heavily pretreated, particularly if they are at least triple-class refractory. When selecting the next line of therapy, it remains essential to consider patient comorbidities and frailty as well as treatment history and disease risk. Fortunately, the myeloma treatment landscape continues to evolve with the development of therapies directed toward new biologic targets, such as B-cell maturation antigen. These new agents, including bispecific T-cell engagers and chimeric antigen receptor T-cell therapy, have shown unprecedented efficacy in late-line myeloma and will be increasingly used at earlier time points. Novel combinations of currently approved treatments, including quadruplets and salvage transplantation, also remain important options for consideration., Introduction Multiple myeloma (MM) is a plasma cell malignancy that remains incurable, but survival is increasing due to ongoing development of new therapies. The median survival of a patient with [...]

Published
2023

12. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Author

Dhakal, Binod, Shah, Nina, Kansagra, Ankit, Kumar, Ambuj, Lonial, Sagar, Garfall, Alfred, Cowan, Andrew, Poudyal, Bishesh Sharma, Costello, Caitlin, Gay, Francesca, Cook, Gordon, Quach, Hang, Einsele, Herman, Schriber, Jeff, Hou, Jian, Costa, Luciano, Aljurf, Mahmoud, Chaudhry, Maria, Beksac, Meral, Prince, Miles, Mohty, Mohamad, Janakiram, Murali, Callander, Natalie, Biran, Noa, Malhotra, Pankaj, Otero, Paula Rodriguez, Moreau, Philippe, Abonour, Rafat, Iftikhar, Raheel, Silberman, Rebecca, Mailankody, Sham, Gregory, Tara, Lin, Yi, Carpenter, Paul, Hamadani, Mehdi, Usmani, Saad, and Kumar, Shaji

Published
2022
Full Text
View/download PDF

13. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Author

Gasparetto, Cristina, Schiller, Gary J., Tuchman, Sascha A., Callander, Natalie S., Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C., Kotb, Rami, White, Darrell, Bahlis, Nizar J., Chen, Christine I., Sutherland, Heather J., Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P., Bensinger, William I., Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S., Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Lipe, Brea

Published
2022
Full Text
View/download PDF

16. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

Author

Costa, Luciano J., Lin, Yi, Cornell, R. Frank, Martin, Thomas, Chhabra, Saurabh, Usmani, Saad Z., Jagannath, Sundar, Callander, Natalie S., Berdeja, Jesus G., Kang, Yubin, Vij, Ravi, Godby, Kelly N., Malek, Ehsan, Neppalli, Amarendra, Liedtke, Michaela, Fiala, Mark, Tian, Hong, Valluri, Satish, Marino, Jennifer, Jackson, Carolyn C., Banerjee, Arnob, Kansagra, Ankit, Schecter, Jordan M., Kumar, Shaji, and Hari, Parameswaran

Published
2022
Full Text
View/download PDF

18. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Author

Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G., Schwartz, Elena I., Reiman, Anthony, Lentzsch, Suzanne, McCarthy, Philip L., Jagannath, Sundar, Yee, Andrew J., Little, Richard F., and Raje, Noopur S.

Published
2022
Full Text
View/download PDF

19. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Author

Wen, Zhi, Rajagopalan, Adhithi, Flietner, Evan D., Yun, Grant, Chesi, Marta, Furumo, Quinlan, Burns, Robert T., Papadas, Athanasios, Ranheim, Erik A., Pagenkopf, Adam C., Morrow, Zachary T., Finn, Remington, Zhou, Yun, Li, Shuyi, You, Xiaona, Jensen, Jeffrey, Yu, Mei, Cicala, Alexander, Menting, James, Mitsiades, Constantine S., Callander, Natalie S., Bergsagel, P. Leif, Wang, Demin, Asimakopoulos, Fotis, and Zhang, Jing

Published
2021
Full Text
View/download PDF

20. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Author

Usmani, Saad Z, Hoering, Antje, Ailawadhi, Sikander, Sexton, Rachael, Lipe, Brea, Hita, Sandi Fredette, Valent, Jason, Rosenzweig, Michael, Zonder, Jeffrey A, Dhodapkar, Madhav, Callander, Natalie, Zimmerman, Todd, Voorhees, Peter M, Durie, Brian, Rajkumar, S Vincent, Richardson, Paul G, and Orlowski, Robert Z

Published
2021
Full Text
View/download PDF

22. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.

Author

Suvannasankha, Attaya, Bahlis, Nizar, Trudel, Suzanne, Weisel, Katja, Koenecke, Christian, Oriol, Albert, Voorhees, Peter M., Alonso, Aranzazu A., Callander, Natalie S., Mateos, María‐Victoria, Reddy, Nishitha, Hakim, Shawn, LaMacchia, John, Patel, Nashita, Williams, Danaé, Jewell, Roxanne C., Zhou, Xiangdong, Gupta, Ira, Opalinska, Joanna, and Nooka, Ajay K.

Subjects
MULTIPLE myeloma, BORTEZOMIB, PEMBROLIZUMAB, PROTEASOME inhibitors
Abstract

Background: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell–mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM. Methods: DREAMM‐4 (NCT03848845) was an open‐label, single‐arm, phase 1/2 study divided into dose‐escalation (part 1) and dose‐expansion (part 2) phases. Patients were ≥18 years old with ≥3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti‐CD38 agent. Patients received belamaf (2.5 or 3.4 mg/kg, part 1; 2.5 mg/kg, part 2) and 200 mg pembrolizumab for ≤35 cycles. Results: Of 41 enrolled patients, 34 (n = 6 part 1, n = 28 part 2) who received 2.5 mg/kg belamaf plus pembrolizumab were included in this final analysis. Sixteen patients (47%) achieved an overall response. Minimal residual disease negativity was achieved in three of 10 patients who had very good partial response or better. Five of eight patients who had prior anti–B‐cell maturation antigen therapy achieved partial response or better, including two who had B‐cell maturation antigen–refractory disease. Common grade ≥3 adverse events were keratopathy (38%) and thrombocytopenia (29%). Despite belamaf‐related ocular events, quality‐of‐life measures remained stable over time. No new safety signals were observed. Conclusions: The results of DREAMM‐4 demonstrated clinical activity and a favorable safety profile of belamaf plus pembrolizumab in patients with RRMM. This trial is registered at www.ClinicalTrials.gov as NCT03848845. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.

Author

Rodriguez-Otero, Paula, Ailawadhi, Sikander, Arnulf, Bertrand, Patel, Krina, Cavo, Michele, Nooka, Ajay K, Manier, Salomon, Callander, Natalie, Costa, Luciano J, Vij, Ravi, Bahlis, Nizar J, Moreau, Philippe, Solomon, Scott R, Delforge, Michel, Berdeja, Jesus, Truppel-Hartmann, Anna, Yang, Zhihong, Favre-Kontula, Linda, Wu, Fan, and Piasecki, Julia

Abstract

Plain language summaryWhat is this summary about? This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed). How was this study conducted? In the KarMMa-3 study, people with relapsed or refractory multiple myeloma received either a one-time infusion of a new treatment, named ide-cel, or one of the standard of care regimens currently available for patients with this cancer. People were treated with the standard of care regimens in weekly or monthly cycles until the cancer got worse, there were unacceptable side effects, or the person withdrew from the study. What were the results? The results of this study showed that people receiving the one-time infusion of ide-cel lived longer without the cancer getting worse and had a greater reduction in cancer cells than patients receiving the standard of care regimen. A higher percentage of patients receiving ide-cel responded to treatment than patients receiving the standard of care regimen, and the response to treatment was better with idecel. These results show that ide-cel is a promising treatment for this challenging disease. Clinical Trial Registration:NCT03651128 (KarMMa-3 study) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Infective endocarditis is rare in patients with hematologic malignancy and neutropenia.

Author

Scolarici, Michael J., Berman, Leigh R., Callander, Natalie, Smith, Jeannina, and Saddler, Christopher

Subjects
INFECTIVE endocarditis, HEMATOLOGIC malignancies, HEMATOPOIETIC stem cell transplantation, NEUTROPENIA, TRANSESOPHAGEAL echocardiography
Abstract

Background: Infective endocarditis (IE) is a serious complication of bloodstream infections (BSIs) that occurs at variable rates depending on the pathogen and clinical setting. There is a paucity of data describing the risk of IE in patients with hematologic malignancy who develop bacteremia while neutropenic. Methods: Adult patients on the hematology ward from January 2018 to December 2020 with hematologic malignancy and bacteremia were evaluated retrospectively for endocarditis by applying the 2023 Duke‐ISCVID criteria. Charts of possible cases were evaluated 90 days after the initial BSI for new infectious complications that could indicate missed IE. Descriptive statistics compared patients admitted for hematopoietic stem cell transplantation (HSCT) to those admitted for alternative reasons (non‐HSCT). Results: Among the 1005 positive blood cultures initially identified, there were 66 episodes in 65 patients with hematologic malignancy and at least grade 3 neutropenia for a mean duration of 11.4 days during their admission. Transthoracic echocardiography (TTE) was performed in 34.8% of BSIs, and transesophageal echocardiography (TEE) in 6.1%. There were no new infectious complications in possible cases 90 days after their initial BSI. No cases of endocarditis were identified. Conclusions: Endocarditis is rare amongst patients with hematologic malignancy, bacteremia, and neutropenia, and no cases were identified in this cohort. The use of routine TTE in this setting seems unwarranted, and the addition of TEE is unlikely to improve patient‐centered outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Kumar, Shaji K, Jacobus, Susanna J, Cohen, Adam D, Weiss, Matthias, Callander, Natalie, Singh, Avina K, Parker, Terri L, Menter, Alexander, Yang, Xuezhong, Parsons, Benjamin, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron, Zonder, Jeffrey A, Faber, Edward, Jr, Lonial, Sagar, Anderson, Kenneth C, Richardson, Paul G, Orlowski, Robert Z, Wagner, Lynne I, and Rajkumar, S Vincent

Published
2020
Full Text
View/download PDF

27. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Author

Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, Usmani, Saad Z, Hari, Parameswaran, Baz, Rachid, Quach, Hang, Moreau, Philippe, Voorhees, Peter M, Gupta, Ira, Hoos, Axel, Zhi, Eric, Baron, January, Piontek, Trisha, Lewis, Eric, Jewell, Roxanne C, Dettman, Elisha J, Popat, Rakesh, Esposti, Simona Degli, Opalinska, Joanna, Richardson, Paul, and Cohen, Adam D

Published
2020
Full Text
View/download PDF

28. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

29. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Author

Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, and Colby, Kathryn

Published
2020
Full Text
View/download PDF

30. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Author

Chhabra, Saurabh, Callander, Natalie, Watts, Nicole L., Costa, Luciano J., Thapa, Bicky, Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Anderson, Larry D., Jr, Bal, Susan, Dhakal, Binod, Nathwani, Nitya, Shah, Nina, Medvedova, Eva, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Schmidt, Timothy, Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Dholaria, Bhagirathbhai, Cornell, R. Frank, Jerkins, James H., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Usmani, Saad Z., Richardson, Paul G., and Voorhees, Peter M.

Published
2023
Full Text
View/download PDF

32. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

33. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

Author

Inamoto, Yoshihiro, Petriček, Igor, Burns, Linda, Chhabra, Saurabh, DeFilipp, Zachariah, Hematti, Peiman, Rovó, Alicia, Schears, Raquel, Shah, Ami, Agrawal, Vaibhav, Ahmed, Aisha, Ahmed, Ibrahim, Ali, Asim, Aljurf, Mahmoud, Alkhateeb, Hassan, Beitinjaneh, Amer, Bhatt, Neel, Buchbinder, Dave, Byrne, Michael, Callander, Natalie, Fahnehjelm, Kristina, Farhadfar, Nosha, Gale, Robert Peter, Ganguly, Siddhartha, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Horn, Erich, Jakubowski, Ann, Kamble, Rammurti T., Law, Jason, Lee, Catherine, Nathan, Sunita, Penack, Olaf, Pingali, Ravi, Prasad, Pinki, Pulanic, Drazen, Rotz, Seth, Shreenivas, Aditya, Steinberg, Amir, Tabbara, Khalid, Tichelli, André, Wirk, Baldeep, Yared, Jean, Basak, Grzegorz W., Battiwalla, Minoo, Duarte, Rafael, Savani, Bipin N., Flowers, Mary E.D., Shaw, Bronwen E., and Valdés-Sanz, Nuria

Published
2019
Full Text
View/download PDF

34. Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Author

Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, and Colby, Kathryn

Published
2020
Full Text
View/download PDF

35. Update on the current and future use of CAR‐T to treat multiple myeloma.

Author

Gahvari, Zhubin, Brunner, Matthew, Schmidt, Timothy, and Callander, Natalie S.

Subjects
MULTIPLE myeloma, CHIMERIC antigen receptors, MEMBRANE proteins, LYMPHOCYTE transformation, PLASMA cells
Abstract

Chimeric antigen receptor T‐cell (CAR‐T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B‐cell maturation antigen (BCMA) is the most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing expression of this essential transmembrane protein on malignant plasma cells as patients develop more advanced disease. This review will explore the earliest CAR‐T trials in myeloma, discuss important issues involved in CAR‐T manufacturing and processing, as well as review current clinical trials that led to the approval of the two commercially available CAR‐T products, Idecabtagene vicleucel and ciltacabtagene autoleucel. The most recent data from trials investigating the use of CAR‐T as an earlier line of therapy will be presented. Finally, the problem of relapses after CAR‐T will be presented, including several theories as to why CAR‐T therapies fail and possible clinical caveats. The next generation of MM‐specific CAR‐T will likely include new targets such as G‐protein‐coupled receptor class C, Group 5, member D (GPRC5D) and signaling lymphocyte activation molecular Family 7 (SLAMF7). The role of CAR‐T in the treatment of MM will undoubtedly increase exponentially in the next decade. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Author

Lonial, Sagar, Nooka, Ajay K., Thulasi, Praneetha, Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Potter, Heather A., Sborov, Douglas, Zaugg, Brian E., Popat, Rakesh, Degli Esposti, Simona, Byrne, Julie, Opalinska, Joanna, Baron, January, Piontek, Trisha, Gupta, Ira, Dana, Reza, Farooq, Asim V., Colby, Kathryn, and Jakubowiak, Andrzej

Published
2021
Full Text
View/download PDF

38. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Author

Gandhi, Ujjawal H., Cornell, Robert F., Lakshman, Arjun, Gahvari, Zhubin J., McGehee, Elizabeth, Jagosky, Megan H., Gupta, Ridhi, Varnado, William, Fiala, Mark A., Chhabra, Saurabh, Malek, Ehsan, Mansour, Joshua, Paul, Barry, Barnstead, Alyssa, Kodali, Saranya, Neppalli, Amarendra, Liedtke, Michaela, Narayana, Swapna, Godby, Kelly N., Kang, Yubin, Kansagra, Ankit, Umyarova, Elvira, Scott, Emma C., Hari, Parameswaran, Vij, Ravi, Usmani, Saad Z., Callander, Natalie S., Kumar, Shaji K., and Costa, Luciano J.

Published
2019
Full Text
View/download PDF

39. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Author

Inamoto, Yoshihiro, Petriček, Igor, Burns, Linda, Chhabra, Saurabh, DeFilipp, Zack, Hematti, Peiman, Rovó, Alicia, Schears, Raquel, Shah, Ami, Agrawal, Vaibhav, Al-Khinji, Aisha, Ahmed, Ibrahim, Ali, Asim, Aljurf, Mahmoud, Alkhateeb, Hassan, Beitinjaneh, Amer, Bhatt, Neel, Buchbinder, Dave, Byrne, Michael, Callander, Natalie, Fahnehjelm, Kristina, Farhadfar, Nosha, Gale, Robert Peter, Ganguly, Siddhartha, Hildebrandt, Gerhard C., Horn, Erich, Jakubowski, Ann, Kamble, Rammurti T., Law, Jason, Lee, Catherine, Nathan, Sunita, Penack, Olaf, Pingali, Ravi, Prasad, Pinki, Pulanic, Drazen, Rotz, Seth, Shreenivas, Aditya, Steinberg, Amir, Tabbara, Khalid, Tichelli, André, Wirk, Baldeep, Yared, Jean, Basak, Grzegorz W., Battiwalla, Minoo, Duarte, Rafael, Savani, Bipin N., Flowers, Mary E. D., Shaw, Bronwen E., and Valdés-Sanz, Nuria

Published
2019
Full Text
View/download PDF

40. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Author

Holstein, Sarah A, Jung, Sin-Ho, Richardson, Paul G, Hofmeister, Craig C, Hurd, David D, Hassoun, Hani, Giralt, Sergio, Stadtmauer, Edward A, Weisdorf, Daniel J, Vij, Ravi, Moreb, Jan S, Callander, Natalie S, van Besien, Koen, Gentile, Teresa G, Isola, Luis, Maziarz, Richard T, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Rodriguez, Cesar, McClune, Brian, Schlossman, Robert L, Smith, Scott E, Hars, Vera, Owzar, Kouros, Jiang, Chen, Boyd, Molly, Schultz, Chelsea, Wilson, Marcia, Hari, Parameswaran, Pasquini, Marcelo C, Horowitz, Mary M, Shea, Thomas C, Devine, Steven M, Linker, Charles, Anderson, Kenneth C, and McCarthy, Philip L

Published
2017
Full Text
View/download PDF

41. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Author

Metheny, Leland, Callander, Natalie S., Hall, Aric C., Zhang, Mei-Jei, Bo-Subait, Khalid, Wang, Hai-Lin, Agrawal, Vaibhav, Al-Homsi, A. Samer, Assal, Amer, Bacher, Ulrike, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Chris, Byrne, Michael, Cairo, Mitchell, Cerny, Jan, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Freytes, César O., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kanakry, Christopher G., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Lee, Jong Wook, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Ringdén, Olov, Rizzieri, David, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Yared, Jean A., Hourigan, Christopher S., Kebriaei, Partow, Litzow, Mark, Sandmaier, Brenda M., Saber, Wael, Weisdorf, Daniel, and de Lima, Marcos

Published
2021
Full Text
View/download PDF

42. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Author

Shahzad, Moazzam, Siddiqui, Raheel S., Anwar, Iqra, Chaudhary, Sibgha Gull, Ali, Tayyaba, Naseem, Masooma, Ahmed, Tehniat F., Ahmed, Zahoor, Khurana, Sharad, Ahmed, Nausheen, Balusu, Ramesh, Singh, Anurag K., Hematti, Peiman, Callander, Natalie S., Abhyankar, Sunil H., McGuirk, Joseph P., and Mushtaq, Muhammad Umair

Published
2021
Full Text
View/download PDF

43. Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma.

Author

Mohan, Meera, Chakraborty, Rajshekhar, Bal, Susan, Nellore, Anoma, Baljevic, Muhamed, D'Souza, Anita, Pappas, Peter G., Berdeja, Jesus G., Callander, Natalie, and Costa, Luciano J.

Subjects
BISPECIFIC antibodies, CHIMERIC antigen receptors, MULTIPLE myeloma, LYMPHOPENIA, INFECTION prevention, T cells
Abstract

Summary: Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T‐cell exhaustion, cytokine‐release syndrome and immune‐effector cell‐associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T‐cell and bispecific antibody therapies in MM patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial.

Author

Nooka, Ajay K., Cohen, Adam D., Lee, Hans C., Badros, Ashraf, Suvannasankha, Attaya, Callander, Natalie, Abdallah, Al‐Ola, Trudel, Suzanne, Chari, Ajai, Libby, Edward N., Chaudhry, Maria, Hultcrantz, Malin, Kortüm, K. Martin, Popat, Rakesh, Sborov, Douglas, Hakim, Shawn, Lewis, Eric, Gorsh, Boris, Bhushan, Bharat, and McKeown, Astrid

Subjects
MULTIPLE myeloma, ANTIBODY-drug conjugates, REFRACTORY materials, PHYSICAL mobility, QUALITY of life
Abstract

Background: Patients with relapsed/refractory multiple myeloma (RRMM) have a high unmet treatment need. Belantamab mafodotin (belamaf), a first‐in‐class, B‐cell maturation antigen‐binding antibody‐drug conjugate, eliminates myeloma cells through direct cell killing and an anti‐myeloma immune response. Methods: DREAMM‐2 (NCT03525678) was a phase 2, two‐arm, open‐label trial in patients with heavily pretreated RRMM who had three or more prior therapies, were refractory to an immunomodulatory agent and a proteasome inhibitor, and refractory or intolerant to an anti‐CD38 monoclonal antibody. Belamaf was given at 2.5 or 3.4 mg/kg every 3 weeks. The primary end point was overall response rate (ORR); secondary end points included progression‐free survival (PFS), overall survival (OS), safety, ocular symptoms, and health‐related quality of life (HRQOL). Results: This final analysis (cutoff date, March 31, 2022), N = 223, with median follow‐up of 12.5 and 13.8 months, demonstrated an ORR of 32% and 35%, median PFS of 2.8 and 3.9 months, and median OS of 15.3 and 14.0 months in the 2.5 mg/kg and 3.4 mg/kg cohorts, respectively. Median duration of response was 12.5 and 6.2 months. No new safety signals were observed; the most common Grade 3 and 4 adverse events were keratopathy (29% vs. 25%), thrombocytopenia (22% vs. 29%), and anemia (21% vs. 28%). HRQOL outcomes suggest that overall global health status/quality of life, physical and role functioning, and overall disease symptoms were maintained or improved during treatment. Conclusions: This final analysis of DREAMM‐2 confirms that in patients with triple‐class refractory RRMM, single‐agent belamaf results in durable and clinically meaningful responses with a manageable safety profile. Although much progress has been made in the treatment landscape for patients with relapsed/refractory multiple myeloma (RRMM), outcomes remain poor once the disease becomes refractory to multiple therapies. The results of the final analysis of the DREAMM‐2 trial further establish that treatment with single‐agent belamaf results in clinically meaningful responses with a manageable safety profile in patients with RRMM who had received at least three previous lines of therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation

Author

Turcotte, Lucie M., Wang, Tao, Hemmer, Michael T., Spellman, Stephen R., Arora, Mukta, Couriel, Daniel, Alousi, Amin, Pidala, Joseph, Abdel-Azim, Hisham, Ahmed, Ibrahim, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Callander, Natalie, Chao, Nelson, Choi, Sung Wong, DeFilipp, Zachariah, Gadalla, Shahinaz M., Gale, Robert Peter, Gergis, Usama, Hashmi, Shahrukh, Hematti, Peiman, Holmberg, Leona, Inamoto, Yoshihiro, Kamble, Rammurti T., Lehmann, Leslie, MacMillan, Margaret A., McIver, Zachariah, Nishihori, Taiga, Norkin, Maxim, O’Brien, Tracey, Olsson, Richard F., Reshef, Ran, Saad, Ayman, Savani, Bipin N., Schouten, Harry C., Seo, Sachiko, Solh, Melhem, Verdonck, Leo, Vij, Ravi, Wirk, Baldeep, Yared, Jean, Horowitz, Mary M., Knight, Jennifer M., and Verneris, Michael R.

Published
2018
Full Text
View/download PDF

46. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Author

Lonial, Sagar, Weiss, Brendan M, Usmani, Saad Z, Singhal, Seema, Chari, Ajai, Bahlis, Nizar J, Belch, Andrew, Krishnan, Amrita, Vescio, Robert A, Mateos, Maria Victoria, Mazumder, Amitabha, Orlowski, Robert Z, Sutherland, Heather J, Bladé, Joan, Scott, Emma C, Oriol, Albert, Berdeja, Jesus, Gharibo, Mecide, Stevens, Don A, LeBlanc, Richard, Sebag, Michael, Callander, Natalie, Jakubowiak, Andrzej, White, Darrell, de la Rubia, Javier, Richardson, Paul G, Lisby, Steen, Feng, Huaibao, Uhlar, Clarissa M, Khan, Imran, Ahmadi, Tahamtan, and Voorhees, Peter M

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results